FY2024 EPS Estimates for AnaptysBio Increased by Analyst

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Research analysts at HC Wainwright lifted their FY2024 EPS estimates for AnaptysBio in a research note issued on Wednesday, November 6th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings of ($6.18) per share for the year, up from their previous forecast of ($6.70). HC Wainwright has a "Buy" rating and a $52.00 price objective on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.84) per share. HC Wainwright also issued estimates for AnaptysBio's Q4 2024 earnings at ($1.70) EPS, FY2025 earnings at ($7.91) EPS, FY2026 earnings at ($10.47) EPS, FY2027 earnings at ($10.55) EPS and FY2028 earnings at ($9.66) EPS.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million.

ANAB has been the subject of several other reports. Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a "hold" rating in a research report on Thursday, August 15th. UBS Group upped their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a "neutral" rating in a report on Wednesday, October 30th. Wedbush reiterated an "outperform" rating and set a $42.00 price target on shares of AnaptysBio in a report on Wednesday. JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Finally, Guggenheim upped their price target on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a "buy" rating in a report on Monday, October 21st. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, AnaptysBio presently has a consensus rating of "Moderate Buy" and a consensus price target of $55.45.

AnaptysBio Price Performance

ANAB traded down $0.18 during trading on Friday, hitting $21.31. 416,110 shares of the stock traded hands, compared to its average volume of 348,299. AnaptysBio has a twelve month low of $13.36 and a twelve month high of $41.31. The company has a market cap of $584.53 million, a price-to-earnings ratio of -3.36 and a beta of -0.24. The business has a 50 day moving average price of $32.66 and a 200 day moving average price of $29.84.

Insider Buying and Selling

In related news, insider Paul F. Lizzul sold 1,500 shares of the business's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now owns 15,398 shares of the company's stock, valued at $595,440.66. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other AnaptysBio news, insider Eric J. Loumeau sold 8,720 shares of the company's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the sale, the insider now owns 7,020 shares of the company's stock, valued at approximately $279,536.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Paul F. Lizzul sold 1,500 shares of the company's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,440 shares of company stock valued at $892,936 over the last 90 days. 33.70% of the stock is owned by insiders.

Institutional Trading of AnaptysBio

A number of institutional investors have recently bought and sold shares of ANAB. Frazier Life Sciences Management L.P. boosted its position in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company's stock valued at $54,270,000 after acquiring an additional 1,265,891 shares during the last quarter. Jennison Associates LLC bought a new position in shares of AnaptysBio during the 3rd quarter worth about $8,874,000. StemPoint Capital LP boosted its position in shares of AnaptysBio by 499.0% during the 1st quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company's stock worth $6,070,000 after purchasing an additional 224,548 shares in the last quarter. Victory Capital Management Inc. boosted its position in shares of AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company's stock worth $7,948,000 after purchasing an additional 206,750 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its position in shares of AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company's stock worth $15,927,000 after purchasing an additional 168,813 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.